Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump

MT Newswires Live

Mar 31, 2025

Corcept Therapeutics (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal, sending shares up more than 90% in recent premarket trading activity.

The company said the study showed a 30% reduction in the risk of disease progression for patients treated with relacorilant and nab-paclitaxel compared to those receiving nab-paclitaxel alone.

The drug developer said the median progression-free survival assessed by blinded independent central review was 6.5 months for the combination therapy group, compared to 5.5 months for those on nab-paclitaxel alone.

In an interim evaluation of overall survival, the company said the combination therapy group showed a significant improvement, with a median overall survival of 16 months versus 11.5 months for the control group.

It added the combination therapy was well-tolerated, with no increased side effect burden.

Corcept said it plans to submit a new drug application for the therapy in Q3.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2523794963"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2523794963\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2523794963?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523794963","market":"sg","top_or_hot":-1,"title":"Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump","media":"MT Newswires Live","content":"<html><body><p> Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal, sending shares up more than 90% in recent premarket trading activity.</p><p>The company said the study showed a 30% reduction in the risk of disease progression for patients treated with relacorilant and nab-paclitaxel compared to those receiving nab-paclitaxel alone.</p><p>The drug developer said the median progression-free survival assessed by blinded independent central review was 6.5 months for the combination therapy group, compared to 5.5 months for those on nab-paclitaxel alone.</p><p>In an interim evaluation of overall survival, the company said the combination therapy group showed a significant improvement, with a median overall survival of 16 months versus 11.5 months for the control group.</p><p>It added the combination therapy was well-tolerated, with no increased side effect burden.</p><p>Corcept said it plans to submit a new drug application for the therapy in Q3.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-31 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal, sending shares up more than 90% in recent premarket trading activity.</p><p>The company said the study showed a 30% reduction in the risk of disease progression for patients treated with relacorilant and nab-paclitaxel compared to those receiving nab-paclitaxel alone.</p><p>The drug developer said the median progression-free survival assessed by blinded independent central review was 6.5 months for the combination therapy group, compared to 5.5 months for those on nab-paclitaxel alone.</p><p>In an interim evaluation of overall survival, the company said the combination therapy group showed a significant improvement, with a median overall survival of 16 months versus 11.5 months for the control group.</p><p>It added the combination therapy was well-tolerated, with no increased side effect burden.</p><p>Corcept said it plans to submit a new drug application for the therapy in Q3.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2523794963","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523794963","pubTimestamp":1743424737,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Corcept Therapeutics  said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal, sending shares up more than 90% in recent premarket trading activity.The company said the study showed a 30% reduction in the risk of disease progression for patients treated with relacorilant and nab-paclitaxel compared to those receiving nab-paclitaxel alone.The drug developer said the median progression-free survival assessed by blinded independent central review was 6.5 months for the combination therapy group, compared to 5.5 months for those on nab-paclitaxel alone.In an interim evaluation of overall survival, the company said the combination therapy group showed a significant improvement, with a median overall survival of 16 months versus 11.5 months for the control group.It added the combination therapy was well-tolerated, with no increased side effect burden.Corcept said it plans to submit a new drug application for the therapy in Q3.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4532":"文艺复兴科技持仓","LU0566484027.USD":"安本美国小盘成长股","BK4007":"制药"},"translate_title":"Corcept Therapeutics的卵巢癌疗法达到3期研究的主要目标；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Corcept Therapeutics (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal, sending shares up more than 90% in recent premarket trading activity.The company said the study showed a 30% reduction in the risk of disease progression for patients treated with relacorilant and nab-paclitaxel compared to those receiving nab-paclitaxel alone.The drug developer said the median progression-free survival assessed by blinded independent central review was 6.5 months for the combination therapy group, compared to 5.5 months for those on nab-paclitaxel alone.In an interim evaluation of overall survival, the company said the combination therapy group showed a significant improvement, with a median overall survival of 16 months versus 11.5 months for the control group.It added the combination therapy was well-tolerated, with no increased side effect burden.Corcept said it plans to submit a new drug application for the therapy in Q3.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}